{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:00:57Z","timestamp":1794992457785,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Silexan is a proprietary active substance produced from <jats:italic>Lavandula angustifolia<\/jats:italic>, with proven anxiolytic efficacy in subthreshold and generalized anxiety disorder as well as in mixed anxiety and depressive disorder with beneficial impact on anxiety-related sleep disturbances. The pharmacological profile and clinical observations suggest that Silexan may also have an antidepressant effect. To investigate the effect of Silexan on co-occurring depressive symptoms, we present a meta-analysis of the five placebo-controlled clinical trials hitherto performed with Silexan in subthreshold anxiety (<jats:italic>n<\/jats:italic>\u2009=\u20093) and anxiety disorders (<jats:italic>n<\/jats:italic>\u2009=\u20092). Patients of all trials received Silexan 1\u2009\u00d7\u200980\u00a0mg\/day or placebo for 10\u00a0weeks according to random assignment. Assessment of the antidepressant effect was based on item \u2018depressed mood\u2019 from the Hamilton Anxiety Rating Scale (HAMA) administered in all trials and on the total scores of the Montgomery \u00c5sberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HAMD) used in three trials. After 10-week treatment, patients receiving Silexan showed significantly more pronounced score reduction for HAMA item \u2018depressed mood\u2019 than those in the placebo group (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). Significant superiority of Silexan over placebo could also be shown for mean MADRS or HAMD total score reduction (three studies; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Silexan-treated patients with more severe depressive symptoms at baseline showed more pronounced improvements than those with milder symptoms. Our meta-analysis clearly shows that Silexan has a beneficial effect on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders and may, hence, lead to important therapeutic implications for depressive disorders.<\/jats:p>","DOI":"10.1007\/s00406-022-01390-z","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T07:02:37Z","timestamp":1646809357000},"page":"51-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-8025","authenticated-orcid":false,"given":"Lucie","family":"Bartova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-2192","authenticated-orcid":false,"given":"Markus","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-8918","authenticated-orcid":false,"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-4426","authenticated-orcid":false,"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"1390_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJL, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382:1575\u20131586","journal-title":"Lancet"},{"key":"1390_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dyu038","volume":"43","author":"Z Steel","year":"2014","unstructured":"Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980\u20132013. Int J Epidemiol 43:476\u2013493","journal-title":"Int J Epidemiol"},{"key":"1390_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593\u2013602","journal-title":"Arch Gen Psychiatry"},{"key":"1390_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"1390_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J\u00f6nsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen H-C (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655\u2013679","journal-title":"Eur Neuropsychopharmacol"},{"key":"1390_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/acps.12801","volume":"136","author":"E Bui","year":"2017","unstructured":"Bui E, Fava M (2017) From depression to anxiety, and back. Acta Psychiatr Scand 136:341\u2013342","journal-title":"Acta Psychiatr Scand"},{"key":"1390_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/da.23113","volume":"38","author":"S Saha","year":"2021","unstructured":"Saha S, Lim CCW, Cannon DL, Burton L, Bremner M, Cosgrove P, Huo YJ, McGrath J (2021) Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis. Depress Anxiety 38:286\u2013306","journal-title":"Depress Anxiety"},{"key":"1390_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1037\/bul0000111","volume":"143","author":"NC Jacobson","year":"2017","unstructured":"Jacobson NC, Newman MG (2017) Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. Psychol Bull 143:1155\u20131200","journal-title":"Psychol Bull"},{"key":"1390_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00406-016-0684-7","volume":"266","author":"H-J M\u00f6ller","year":"2016","unstructured":"M\u00f6ller H-J, Bandelow B, Volz H-P, Barnikol UB, Seifritz E, Kasper S (2016) The relevance of \u201cmixed anxiety and depression\u201d as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 266:725\u2013736","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1390_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2016.08.006","volume":"216","author":"K Kircanski","year":"2017","unstructured":"Kircanski K, LeMoult J, Ordaz S, Gotlib IH (2017) Investigating the nature of co-occurring depression and anxiety: comparing diagnostic and dimensional research approaches. J Affect Disord 216:123\u2013135","journal-title":"J Affect Disord"},{"key":"1390_CR11","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1017\/S0033291716002300","volume":"46","author":"C Beard","year":"2016","unstructured":"Beard C, Millner AJ, Forgeard MJ, Fried EI, Hsu KJ, Treadway MT, Leonard CV, Kertz SJ, Bj\u00f6rgvinsson T (2016) Network analysis of depression and anxiety symptom relationships in a psychiatric sample. Psychol Med 46:3359\u20133369","journal-title":"Psychol Med"},{"key":"1390_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355","journal-title":"Br J Med Psychol"},{"key":"1390_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278\u2013296","journal-title":"Br J Soc Clin Psychol"},{"key":"1390_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.janxdis.2016.09.008","volume":"46","author":"AM Talkovsky","year":"2017","unstructured":"Talkovsky AM, Green KL, Osegueda A, Norton PJ (2017) Secondary depression in transdiagnostic group cognitive behavioral therapy among individuals diagnosed with anxiety disorders. J Anxiety Disord 46:56\u201364","journal-title":"J Anxiety Disord"},{"key":"1390_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/YIC.0000000000000256","volume":"34","author":"GJ Lyndon","year":"2019","unstructured":"Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B (2019) Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol 34:110\u2013118","journal-title":"Int Clin Psychopharmacol"},{"key":"1390_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S (2019) Results of the European Group for the Study of Resistant Depression (GSRD)\u2014basis for further research and clinical practice. World J Biol Psychiatry 20:427\u2013448","journal-title":"World J Biol Psychiatry"},{"key":"1390_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.02.020","volume":"91","author":"M Dold","year":"2017","unstructured":"Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S (2017) Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders\u2014results from a european multicenter study. J Psychiatr Res 91:1\u201313","journal-title":"J Psychiatr Res"},{"key":"1390_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/acps.12959","volume":"139","author":"A Kautzky","year":"2019","unstructured":"Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Dikeos D, Rujescu D, Kasper S (2019) Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand 139:78\u201388","journal-title":"Acta Psychiatr Scand"},{"key":"1390_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/acps.13250","volume":"143","author":"A Kautzky","year":"2021","unstructured":"Kautzky A, M\u00f6ller H-J, Dold M, Bartova L, Seem\u00fcller F, Laux G, Riedel M, Gaebel W, Kasper S (2021) Combining machine learning algorithms for prediction of antidepressant treatment response. Acta Psychiatr Scand 143:36\u201349","journal-title":"Acta Psychiatr Scand"},{"key":"1390_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-244X-14-128","volume":"14","author":"H Haller","year":"2014","unstructured":"Haller H, Cramer H, Lauche R, Gass F, Dobos GJ (2014) The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry 14:128","journal-title":"BMC Psychiatry"},{"key":"1390_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2215-0366(15)00092-9","volume":"2","author":"SM Meier","year":"2015","unstructured":"Meier SM, Petersen L, Mattheisen M, Mors O, Mortensen PB, Laursen TM (2015) Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark. Lancet Psychiatry 2:515\u2013523","journal-title":"Lancet Psychiatry"},{"issue":"Suppl 1","key":"1390_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4","volume":"12","author":"KJ Ressler","year":"2000","unstructured":"Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl 1):2\u201319","journal-title":"Depress Anxiety"},{"key":"1390_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neuint.2011.05.002","volume":"59","author":"L Musazzi","year":"2011","unstructured":"Musazzi L, Racagni G, Popoli M (2011) Stress, glucocorticoids and glutamate release: effects of antidepressant drugs. Neurochem Int 59:138\u2013149","journal-title":"Neurochem Int"},{"key":"1390_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","volume":"66","author":"E Akimova","year":"2009","unstructured":"Akimova E, Lanzenberger R, Kasper S (2009) The serotonin-1a receptor in anxiety disorders. Biol Psychiatry 66:627\u2013635","journal-title":"Biol Psychiatry"},{"key":"1390_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","volume":"88","author":"J Savitz","year":"2009","unstructured":"Savitz J, Lucki I, Drevets WC (2009) 5-ht(1a) receptor function in major depressive disorder. Prog Neurobiol 88:17\u201331","journal-title":"Prog Neurobiol"},{"issue":"Suppl 2","key":"1390_CR26","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/00004850-200008002-00007","volume":"15","author":"M Berk","year":"2000","unstructured":"Berk M (2000) Selective serotonin reuptake inhibitors in mixed anxiety-depression. Int Clin Psychopharmacol 15(Suppl 2):S41-45","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 8","key":"1390_CR27","first-page":"20","volume":"58","author":"SM Stahl","year":"1997","unstructured":"Stahl SM (1997) Mixed depression and anxiety: Serotonin1a receptors as a common pharmacologic link. J Clin Psychiatry 58(Suppl 8):20\u201326","journal-title":"J Clin Psychiatry"},{"key":"1390_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, M\u00f6ller HJ, WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD and PTSD (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77\u201384","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1390_CR29","doi-asserted-by":"publisher","first-page":"153099","DOI":"10.1016\/j.phymed.2019.153099","volume":"65","author":"D Donelli","year":"2019","unstructured":"Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F (2019) Effects of lavender on anxiety: a systematic review and meta-analysis. Phytomedicine 65:153099","journal-title":"Phytomedicine"},{"key":"1390_CR30","first-page":"295","volume":"13","author":"H-J Kang","year":"2019","unstructured":"Kang H-J, Nam ES, Lee Y, Kim M (2019) How strong is the evidence for the anxiolytic efficacy of lavender?: Systematic review and meta-analysis of randomized controlled trials. Asian Nurs Res (Korean Soc Nurs Sci) 13:295\u2013305","journal-title":"Asian Nurs Res (Korean Soc Nurs Sci)"},{"key":"1390_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00406-017-0852-4","volume":"269","author":"H-J M\u00f6ller","year":"2019","unstructured":"M\u00f6ller H-J, Volz H-P, Dienel A, Schl\u00e4fke S, Kasper S (2019) Efficacy of silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 269:183\u2013193","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1390_CR32","doi-asserted-by":"publisher","first-page":"5418586","DOI":"10.1155\/2020\/5418586","volume":"2020","author":"K Ogata","year":"2020","unstructured":"Ogata K, Ataka K, Suzuki H, Yagi T, Okawa A, Fukumoto T, Zhang B, Nakata M, Yada T, Asakawa A (2020) Lavender oil reduces depressive mood in healthy individuals and enhances the activity of single oxytocin neurons of the hypothalamus isolated from mice: a preliminary study. Evid Based Complement Altern Med 2020:5418586","journal-title":"Evid Based Complement Altern Med"},{"key":"1390_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.genhosppsych.2020.02.001","volume":"64","author":"AM Sayed","year":"2020","unstructured":"Sayed AM, Morsy S, Tawfik GM, Naveed S, Minh-Duc NT, Hieu TH, Ali ZA, Shinkar A, Doheim MF, Hashan MR, Huy NT (2020) The best route of administration of lavender for anxiety: a systematic review and network meta-analysis. Gen Hosp Psychiatry 64:33\u201340","journal-title":"Gen Hosp Psychiatry"},{"key":"1390_CR34","doi-asserted-by":"publisher","first-page":"18042","DOI":"10.1038\/s41598-019-54529-9","volume":"9","author":"WS Yap","year":"2019","unstructured":"Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM (2019) Efficacy and safety of lavender essential oil (silexan) capsules among patients suffering from anxiety disorders: a network meta-analysis. Sci Rep 9:18042","journal-title":"Sci Rep"},{"key":"1390_CR35","doi-asserted-by":"publisher","first-page":"e59998","DOI":"10.1371\/journal.pone.0059998","volume":"8","author":"AM Schuwald","year":"2013","unstructured":"Schuwald AM, N\u00f6ldner M, Wilmes T, Klugbauer N, Leuner K, M\u00fcller WE (2013) Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS ONE 8:e59998","journal-title":"PLoS ONE"},{"key":"1390_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/a0026517","volume":"12","author":"AB Satpute","year":"2012","unstructured":"Satpute AB, Mumford JA, Naliboff BD, Poldrack RA (2012) Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. Emotion 12:58\u201368","journal-title":"Emotion"},{"key":"1390_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu063","volume":"18","author":"P Baldinger","year":"2015","unstructured":"Baldinger P, H\u00f6flich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S (2015) Effects of silexan on the serotonin-1a receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol 18:1\u20139","journal-title":"Int J Neuropsychopharmacol"},{"key":"1390_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1055\/s-0030-1264952","volume":"76","author":"J Kehr","year":"2010","unstructured":"Kehr J, Yoshitake T, Koch E, Noeldner M (2010) Effects of intraperitoneal administration of silexan, an essential oil from flowers of lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats. Planta Med 76:1316\u20131316","journal-title":"Planta Med"},{"key":"1390_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/15622975.2017.1331046","volume":"19","author":"S Kasper","year":"2018","unstructured":"Kasper S, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 19:412\u2013420","journal-title":"World J Biol Psychiatry"},{"key":"1390_CR40","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.neuint.2020.104899","volume":"143","author":"WE M\u00fcller","year":"2021","unstructured":"M\u00fcller WE, Sillani G, Schuwald A, Friedland K (2021) Pharmacological basis of the anxiolytic and antidepressant properties of silexan\u00ae, an essential oil from the flowers of lavender. Neurochem Int 143:104899","journal-title":"Neurochem Int"},{"key":"1390_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/YIC.0000000000000176","volume":"32","author":"S Kasper","year":"2017","unstructured":"Kasper S, M\u00f6ller H-J, Volz H-P, Schl\u00e4fke S, Dienel A (2017) Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 32:195\u2013204","journal-title":"Int Clin Psychopharmacol"},{"key":"1390_CR42","doi-asserted-by":"publisher","first-page":"V01","DOI":"10.1055\/s-0033-1338176","volume":"34","author":"S Kasper","year":"2013","unstructured":"Kasper S, Dienel A (2013) Silexan (ws\u00ae 1265) vermindert begleitende depressive symptome bei patienten mit angsterkrankungen. Z Phytother 34:V01","journal-title":"Z Phytother"},{"key":"1390_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/a-1293-8585","volume":"54","author":"K Friedland","year":"2021","unstructured":"Friedland K, Silani G, Schuwald A, Stockburger C, Koch E, N\u00f6ldner M, M\u00fcller WE (2021) Neurotrophic properties of silexan, an essential oil from the flowers of lavender-preclinical evidence for antidepressant-like properties. Pharmacopsychiatry 54:37\u201346","journal-title":"Pharmacopsychiatry"},{"key":"1390_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jpsychires.2019.04.013","volume":"115","author":"E Seifritz","year":"2019","unstructured":"Seifritz E, Schl\u00e4fke S, Holsboer-Trachsler E (2019) Beneficial effects of silexan on sleep are mediated by its anxiolytic effect. J Psychiatr Res 115:69\u201374","journal-title":"J Psychiatr Res"},{"key":"1390_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctim.2013.11.008","volume":"22","author":"M Fi\u00dfler","year":"2014","unstructured":"Fi\u00dfler M, Quante A (2014) A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety. Complement Ther Med 22:63\u201369","journal-title":"Complement Ther Med"},{"issue":"4","key":"1390_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1997","volume":"11","author":"R von K\u00e4nel","year":"2021","unstructured":"von K\u00e4nel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, H\u00e4ttenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E (2021) Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: a meta-analysis. Brain Behav 11(4):e01997. https:\/\/doi.org\/10.1002\/brb3.1997","journal-title":"Brain Behav"},{"key":"1390_CR47","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.euroneuro.2015.07.024","volume":"25","author":"S Kasper","year":"2015","unstructured":"Kasper S, Anghelescu I, Dienel A (2015) Efficacy of orally administered silexan in patients with anxiety-related restlessness and disturbed sleep\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25:1960\u20131967","journal-title":"Eur Neuropsychopharmacol"},{"key":"1390_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","volume":"25","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Dienel A, Schl\u00e4fke S (2010) Silexan, an orally administered lavandula oil preparation, is effective in the treatment of \u2018subsyndromal\u2019 anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25:277\u2013287","journal-title":"Int Clin Psychopharmacol"},{"key":"1390_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1017\/S1461145714000017","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Schl\u00e4fke S, Dienel A (2014) Lavender oil preparation silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17:859\u2013869","journal-title":"Int J Neuropsychopharmacol"},{"key":"1390_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.euroneuro.2015.12.002","volume":"26","author":"S Kasper","year":"2016","unstructured":"Kasper S, Volz H-P, Dienel A, Schl\u00e4fke S (2016) Efficacy of silexan in mixed anxiety-depression\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 26:331\u2013340","journal-title":"Eur Neuropsychopharmacol"},{"key":"1390_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"1390_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00005053-196901000-00010","volume":"148","author":"A Raskin","year":"1969","unstructured":"Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969) Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148:87\u201398","journal-title":"J Nerv Ment Dis"},{"key":"1390_CR53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1192\/bjp.148.5.599","volume":"148","author":"RP Snaith","year":"1986","unstructured":"Snaith RP, Harrop FM, Newby DA, Teale C (1986) Grade scores of the montgomery-asberg depression and the clinical anxiety scales. Br J Psychiatry 148:599\u2013601","journal-title":"Br J Psychiatry"},{"key":"1390_CR54","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013) Severity classification on the hamilton depression rating scale. J Affect Disord 150:384\u2013388","journal-title":"J Affect Disord"},{"key":"1390_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD (2017) Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 36:855\u2013875","journal-title":"Stat Med"},{"key":"1390_CR56","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221","journal-title":"BMJ"},{"key":"1390_CR57","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2020) Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Eds.). Cochrane handbook for systematic reviews of interventions version 61 (updated September 2020). The cochrane collaboration, Available from www.training.cochrane.org\/handbook"},{"key":"1390_CR58","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22:238\u2013249","journal-title":"Nat Med"},{"key":"1390_CR59","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","volume":"4","author":"CJ Harmer","year":"2017","unstructured":"Harmer CJ, Duman RS, Cowen PJ (2017) How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 4:409\u2013418","journal-title":"Lancet Psychiatry"},{"key":"1390_CR60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jep.2012.07.026","volume":"143","author":"SL Guzm\u00e1n-Guti\u00e9rrez","year":"2012","unstructured":"Guzm\u00e1n-Guti\u00e9rrez SL, G\u00f3mez-Cansino R, Garc\u00eda-Zebad\u00faa JC, Jim\u00e9nez-P\u00e9rez NC, Reyes-Chilpa R (2012) Antidepressant activity of litsea glaucescens essential oil: Identification of \u03b2-pinene and linalool as active principles. J Ethnopharmacol 143:673\u2013679","journal-title":"J Ethnopharmacol"},{"key":"1390_CR61","volume-title":"Research synthesis and meta-analysis: a step-by-step approach. Applied social research methods series","author":"HM Cooper","year":"2009","unstructured":"Cooper HM (2009) Research synthesis and meta-analysis: a step-by-step approach. Applied social research methods series, 4th edn. Sage, Thousand Oaks","edition":"4"},{"issue":"2","key":"1390_CR62","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3758\/s13428-012-0261-6","volume":"45","author":"W Van den Noortgate","year":"2013","unstructured":"Van den Noortgate W, L\u00f3pez-L\u00f3pez JA, Mar\u00edn-Mart\u00ednez F, S\u00e1nchez-Meca J (2013) Three-level meta-analysis of dependent effect sizes. Behav Res Methods 45(2):576\u2013594","journal-title":"Behav Res Methods"},{"issue":"1","key":"1390_CR63","doi-asserted-by":"publisher","first-page":"18042","DOI":"10.1038\/s41598-019-54529-9","volume":"9","author":"WS Yap","year":"2019","unstructured":"Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM (2019) Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: a network meta-analysis. Sci Rep 9(1):18042","journal-title":"Sci Rep"},{"issue":"2","key":"1390_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00406-019-00987-1","volume":"269","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K (2019) Impact of FAAH gene, hyperactivation in emotion processing brain regions and Lavender oil preparation Silexan in anxiety. Eur Arch Psychiatry Clin Neurosci 269(2):145\u2013146","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1390_CR65","first-page":"100","volume":"17","author":"L Covi","year":"1981","unstructured":"Covi L, Rickels K, Lipman RS, McNair DM, Smith VK, Downing R, Kahn R, Fisher S (1981) Effects of psychotropic agents on primary depression. Psychopharmacol Bull 17:100\u2013103","journal-title":"Psychopharmacol Bull"},{"key":"1390_CR66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389","journal-title":"Br J Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01390-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T05:16:28Z","timestamp":1677215788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01390-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01390-z","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>LB<\/i> has received travel grants and consultant\/speaker honoraria from AOP Orphan, Medizin Medien Austria, Vertretungsnetz, Schwabe Austria, Janssen and Angelini. <i>MD<\/i> has received travel grants and consultant\/speaker honoraria from Janssen-Cilag. Within the last 3\u00a0years, <i>H-PV<\/i> has served as a consultant or on advisory boards for Astra\/Zeneca, Eli Lilly, Lundbeck, Pfizer, Schwabe, Janssen, Otsuka, Angelini, and Sage and has served on speakers\u2019 bureaus for Astra\/Zeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Bayer, Recordati and neuraxpharm. <i>ES<\/i> received in the last 3\u00a0years honoraria and grants for advice and educational lectures from Lundbeck Switzerland, Schwabe Switzerland and Germany, Janssen Switzerland, Otsuka Switzerland, Mepha Pharma Switzerland, Otsuka Pharma Switzerland, Ricordati Switzerland and Sunovion Pharma UK and Angelini. <i>H-JM<\/i> has received grant\/research support, consulting fees and honoraria within the last years from AstraZeneca, Lundbeck, Otsuka, and Schwabe. <i>SK<\/i> has received grant\/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speakers bureaus for Aspen Farmaceutica S.A., Angelini, Biogen, Janssen, Lundbeck, Neuraxpharma, Recordati, Sage, Sanofi, Schwabe, Servier and Sun Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our research complies with internationally accepted standards for research practice and reporting. The present investigation was carried out in accordance with the latest version of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}